Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis
Metrics: PDF 730 views | HTML 1250 views | ?
Bin Li1, Xunbo Jin1, Huilin Meng1, Bo Hu1, Tao Zhang1, Jiang Yu1, Shaoan Chen1, Xudong Guo1, Weiguo Wang2, Wei Jiang3 and Jin Wang4,5
1Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
2Department of Urology, Jining No.1 People’s Hospital, Jining 272011, Shandong, China
3Department of Urology, Dongying People’s Hospital, Dongying 257091, Shandong, China
4Department of Urology, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China
5School of Basic Medical Sciences, Shandong University, Jinan 250012, Shandong, China
Jin Wang, email: email@example.com
Keywords: prostate cancer, morin, paclitaxel-resistance, microRNA (miR)-155, GATA binding protein 3 (GATA3)
Received: February 28, 2017 Accepted: April 21, 2017 Published: May 24, 2017
Paclitaxel is a first-line microtubule-stabilizing drug in treating prostate cancer. However, most patients develop resistance and experience relapse. Morin (3,5,7,20,40-pentahydroxyflavone) is an anti-tumor flavonoid in a numerous types of cancer cells including breast, ovarian and lung cancers. We therefore researched the effects of morin as an adjuvant to paclitaxel in in treating DU145 and PC-3 cells in vitro and DU145 derived prostate cancers in nude mice models. The chemosensitivities of these cells to the treatments of morin and paclitaxel were tested through viability assays utilizing cell counting kit 8 (CCK-8) and apoptosis assays through flow cytometry analyses. MicroRNA (miRNA) microarray was employed to determine the changes in miRNA profile of morin treated DU145 cells. The results from microarrays were further certified by quantitative real-time reverse transcription-PCR (qRT-PCR). The underlying targets of miR-155 were verified using luciferase assays followed by Western blot assays. In the results, morin was capable of repressing the cell viabilities in the paclitaxel-treated cells. MiR-155might be an effective target that can be down-regulated in morin-treated cells. We also discovered that GATA binding protein 3 (GATA3) was directly repressed by miR-155, and the treatment of morin reversed the expression of GATA3. In conclusion, morin might be a potential adjuvant of paclitaxel in treating prostate cancer through regulating miR-155/GATA3 axis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.